Traduction de «al analysis of pooled » (Français → Néerlandais) :

21. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis.
Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis.

scope and purpose: 10/12 stakeholders involvement: 8/16 rigour of development: 7/28 (methods available only on request) clarity and presentation: 8/16 applicability: 3/12 editorial independence: 2/8 question: adequate search: insufficient selection: unclear quality appraisal: fair data-extraction: not given characteristics of original studies: not given meta-analysis: no pooling
scope and purpose: 10/12 stakeholders involvement: 8/16 rigour of development: 7/28 (methods available only on request) clarity and presentation: 8/16 applicability: 3/12 editorial independence: 2/8 question: adequate search: insufficient selection: unclear quality appraisal: fair data-extraction: not given characteristics of original studies: not given meta-analysis: no pooling Randomisation: good concealment of allocation: no Blinding of outcome assessors: unclear Baseline characteristics comparable: yes Follow-up: sufficient Intention-to-treat: yes Contamination: unclear

R.W. Schrier en R.O. Estacio: The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials (Editorial) Ann Intern Med 135 : 138-139(2001)
R.W. Schrier en R.O. Estacio: The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials (Editoriaal) Ann Intern Med 135 : 138-139(2001)

DÊaprès les résultats de ces études, un pooled positive likelihood ratio de 3,48 (95%CI 1,66 à 7,27) et un pooled negative likelihood ratio de 0,6 (95%CI 0,45 à 0,8) ont été calculés pour la prédiction de la protéinurie (300mg/24h).
Uit de resultaten van deze studies werd een pooled positive likelihood ratio van 3.48 (95%CI 1.66 to 7.27) en een pooled negative likelihood ratio van 0.6 (95%CI 0.45 to 0.8) voor de predictie van (300mg/24u) proteïnurie berekend. 26

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

Table 3: Search for SR and MA Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for systematic reviews and meta-analysis Date 19/04/2010 Keywords Breast neoplasms (MESH) and mass screening (or early detection) (MESH) and mammography (MESH) Medline 1 meta-analysis.pt,ti,ab,sh (34320) 27 (1 duplicate) (OVID): 2 1 or (meta anal$ or metaanal$).ti,ab,sh (43943) Filter 3 (methodol$ or systematic$ or quantitativ$).ti,ab,sh.
Table 1: Search for SR and MA Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for systematic reviews and meta-analysis Date 19/04/2010 Keywords Breast neoplasms (MESH) and mass screening (or early detection) (MESH) and mammography (MESH) Medline 1 meta-analysis.pt,ti,ab,sh (34320) 27 (1 duplicate) (OVID): 2 1 or (meta anal$ or metaanal$).ti,ab,sh (43943) Filter 3 (methodol$ or systematic$ or quantitativ$).ti,ab,sh.

Table 9: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence
Table 7: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence

Les études étaient très hétérogènes en ce qui concerne les populations étudiées et les critères d’évaluation; une analyse globale des résultats (" pooling" ) n’a donc pas été possible.
De studies bleken zeer heterogeen qua populatie en uitkomst; bijgevolg kon er geen groepsgewijze analyse (" pooling" ) van de resultaten gebeuren.

Nannini L, Cates CJ, Lasserson TJ, Poole P: Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease (Cochrane review).
Nannini L, Cates CJ, Lasserson TJ, Poole P.: Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease (Cochrane review).

Pooled negative likelihood ratio for predicting 300 mg/24- hour proteinuria at the 1+ or greater threshold
the results of the determine posttest 300 mg/24- hour diagnostic test of probabilities proteinuria at interest were the 1+ or greater compared with threshold the results of a „reference standard‰